StemCellAtlasPowered by Stem Plus Clinic · Sofia, EU Get matched with the clinic
☰
Treatments Cell therapies Who we help Costs Cost calculator Data Guides Journal Get matched with the clinic
Home › Cell therapies › Fibroblasts from Wharton's Jelly
Cell therapies

Fibroblasts from Wharton's Jelly: how this cell therapy works, evidence & cost

regenerative fibroblasts from umbilical-cord tissue. Cell-free exosomes and iPSC-derived products are the fastest-growing area in 2026 — easier to manufacture and store, with 200+ active trials — though most uses remain investigational.

Fibroblasts isolated from Wharton's jelly—the gelatinous connective tissue of umbilical cords—present a young, energetic cell population that retains heightened regenerative signalling properties. Unlike fibroblasts harvested from adult skin or other aged tissues, umbilical-cord fibroblasts secrete elevated levels of anti-inflammatory cytokines and growth factors that may promote tissue remodelling and angiogenesis. They are abundant within cord tissue and relatively easy to expand, making them an accessible and scalable source. The cells are naturally allogeneic—derived from donated cords—and their immunological profile suggests lower rejection risk than might be expected, though long-term immunological tolerance is still being characterised. In vitro studies show these fibroblasts enhance collagen remodelling and produce bioactive molecules implicated in wound healing and vascularisation. Clinical interest has centred on chronic wound repair, cosmetic rejuvenation, and tissue damage from inflammation or fibrosis. However, their role remains largely supportive: they work via paracrine signalling—secreting beneficial factors—rather than direct structural integration into tissue. Their effectiveness in human studies is still being documented, and optimal dosing, frequency, and combination therapies with other interventions remain active research questions.

Conditions where Fibroblasts from Wharton's Jelly are explored

Aesthetic & Anti-AgeingHair Loss & RestorationChronic Wounds & Ulcers

Evidence & approval status

For most conditions, therapy using Fibroblasts from Wharton's Jelly is investigational — not an approved cure — outside established blood/immune transplantation. Check the published evidence and whether a registered trial is open with our candidacy check and cell-type selector.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

Educational information only. Fibroblasts from Wharton's Jelly protocols for most conditions remain investigational; outcomes vary by patient. Not medical advice.

Explore

Muse CellsChondrocytesFetal Stem CellsNeurogenic CellsMSCs from Amniotic MembraneWhich cell type?Cost calculatorAll conditions

Compare stem-cell therapy by country, cost and evidence — in one place.

StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.

Get an honest assessment